alprazolam + selective serotonin reuptake inhibitor + serotonin-norepinephrine reuptake inhibitor

Combination drug therapy consisting of alprazolam (a benzodiazepine), a selective serotonin reuptake inhibitor (SSRI), and a serotonin-norepinephrine reuptake inhibitor (SNRI). **Alprazolam** acts as a central nervous system depressant by potentiating gamma-aminobutyric acid (GABA) activity at the GABA-A receptor, resulting in anxiolytic, sedative, and muscle relaxant effects. **SSRIs** inhibit presynaptic serotonin reuptake, enhancing serotonergic neurotransmission, and are primarily used in depressive and anxiety disorders. **SNRIs** inhibit both serotonin and norepinephrine reuptake, affecting neurotransmission of both. The combination is sometimes used, especially in panic disorder, to achieve more rapid symptom improvement compared to monotherapy with either SSRIs or SNRIs alone. It may also be associated with increased risk of adverse effects, including somnolence, headache, and potential for serotonin syndrome[1][2][3].